Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 1Oligodendroglioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 115Radiotherapy 63Magnetic Resonance Spectroscopy 30Carboplatin 30Bevacizumab 30Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 18Lomustine 17Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × etirinotecan pegol × CNS × Clear all
NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡